# 

# How RWE can inform the drug discovery process

#### **Johan Liwing**

Director RWE Market Access Partnerships Global Commercial Strategy Organization Janssen Pharmaceutical Companies of J&J Budapest March 17, 2016 Dorethey Gorham, *Day of the Armada* Dorethey is a joyful, self-taught artist living with arthritis, general anxiety syndrome, and diabetes.



# **Janssen's Global Real World Evidence Network**

#### Real World Evidence research can uncover outcomes, unmet needs and clues for current therapies and future medical breakthroughs

**Janssen** is partnering with top institutions worldwide to accelerate this new line of research.

Our network aims to:


- Generate evidence about **disease pathways, healthcare delivery and the effects of medical interventions**
- Apply scientific **best practices** and advance **methodologies**
- Support medical decisions
- Analyze multiple sources of data from multiple stakeholders






harmaceutical compa of JohmonaJohmon


# **Disease Interception is a paradigm shift**




## **A Generalized Disease Interception Model**







## Multiple AAb in combination with increases in HbA1c Predicts progression to Insulin Dependence



HbA1c Predicts Time to Diagnosis of Type 1 Diabetes in Children at Risk. Helminen O, Aspholm S, Pokka T, Hautakangas MR, Haatanen N, Lempainen J, Ilonen J, Simell O, Knip M, Veijola R. Diabetes. 2015 May;64(5):1719-27.



### **Summary**

• We believe in open and transparent collaboration in areas of common interest

In the (near) future

- Drug discovery will be heavily informed by the insights generated by real word data
- Society/patients will demand data-based interventions



pharmaceutical companies of Johnson Johnson